Question 1

Why does the calculator jump straight to 4 mg/day for high-risk users?

Accepted Answer

ACOG Practice Bulletin No. 187 (PMID 29189693) and the MRC Vitamin Study (PMID 1677062, 72% recurrence reduction) established 4000–5000 µg/day folic acid for women with prior NTD-affected pregnancies. The same high-risk dose extends by clinical convention to BMI ≥30, pre-existing diabetes, and anti-epileptic drug therapy — all independent NTD risk factors that the standard 400–800 µg/day target undertreats. The 10× dose escalation is supported by FDA Category A safety data and the absence of any toxicity syndrome at 5 mg/day folic acid.

Question 2

What if I have multiple high-risk factors — does the dose stack?

Accepted Answer

No. The risk stratification is single-gate — any one of {prior NTD pregnancy, BMI ≥30, diabetes, AED} sets the ceiling at 4000–5000 µg/day. Multiple risk factors do not escalate further. The dose ceiling is set by neural-tube biology (the available folate already saturates the relevant pathways at 4 mg/day) and not by stacked risk math. The calculator surfaces all triggering factors so you can see why you're in the high-risk tier, but the dose itself doesn't change.

Question 3

Folic acid or 5-MTHF — does the form matter?

Accepted Answer

For most people, no. Folic acid is the gold standard — most studied (MRC 1991, Czeizel 1992, Cochrane 2015 PMID 26662928), cheapest ($3–10/month), and adequate at standard doses. 5-MTHF (L-methylfolate) is biochemically superior in two situations: MTHFR C677T TT homozygotes (10–15% of Caucasians, 50–70% reduced enzyme activity converting folic acid to its active form) and AED users (anti-epileptic drugs inhibit DHFR, the conversion enzyme). The calculator forces 5-MTHF in those cases and recommends folic acid otherwise. The folic acid vs 5-MTHF debate is commercially charged — patent holders (Quatrefolic, Metafolin) benefit from MTHFR anxiety — so be skeptical of marketing that frames folic acid as inferior for the general population.

Question 4

Why start 3 months before conception?

Accepted Answer

RBC folate concentrations reach steady-state in approximately 12 weeks of consistent supplementation. The neural tube closes between days 21 and 28 post-conception — before most women know they're pregnant. Starting at conception means RBC folate is still climbing during the critical neurulation window. The 3-month preconception lead-time ensures peak folate status before the closing window opens. If you're already pregnant and weren't supplementing, start immediately — partial protection is better than none, and the standard 400–800 µg/day target still applies through gestational week 12.

Question 5

Why does the calculator insist on checking B12 before high-dose folate?

Accepted Answer

High-dose folic acid can correct megaloblastic anemia (the hematologic signal of B12 deficiency) while B12-related neurological damage progresses silently. This is the classic "B12 masking" trap. By the time neurological symptoms manifest, peripheral neuropathy and subacute combined degeneration of the cord may be irreversible. Confirm serum B12 >300 pg/mL or active-B12/holotranscobalamin in range before starting any dose >1000 µg/day folic acid. This is the single most important pre-treatment safety step in high-risk preconception folate dosing — non-negotiable.

Question 6

I'm on phenytoin/carbamazepine for epilepsy. What about anticonvulsant levels?

Accepted Answer

AED users get 5-MTHF (DHFR-bypass) at 4000–5000 µg/day per ACOG, but the start needs neurologist supervision. Folate can lower phenytoin and carbamazepine serum levels and may destabilize seizure control if started abruptly at high dose. Never start without therapeutic-drug-monitoring planned at 4 and 12 weeks after initiation. Some AED-folate combinations are safer than others (lamotrigine and levetiracetam have less interaction); the prescribing neurologist should make the call. The calculator surfaces this as a hard amber flag — do not bypass it.

Question 7

For hyperhomocysteinemia, why does the calculator say folate works on the biomarker but not on outcomes?

Accepted Answer

Folate (with B12 and B6) reliably lowers plasma homocysteine by ~25–30% — that's a robust biochemical effect demonstrated across 25+ RCTs and the Clarke 2010 meta-analysis (PMID 20937919, n=37,485, 8 large RCTs). However, that biomarker reduction did NOT translate into significant reduction in major cardiovascular events (RR 1.01), coronary events (RR 1.03), stroke (RR 0.96), cancer incidence (RR 1.05), or all-cause mortality (RR 1.02) over 5 years of follow-up in fortified populations. This is the biomarker-vs-outcome divergence. The calculator surfaces it explicitly so you can decide based on your population context (the CSPPT trial in non-fortified China DID show 21% stroke reduction). Don't assume biomarker improvement equals clinical benefit — the literature is clear it doesn't, in most cases.

Question 8

On methotrexate for rheumatoid arthritis — is folic acid safe? Does it kill MTX efficacy?

Accepted Answer

Folic acid is the standard of care alongside low-dose MTX for RA, psoriasis, and IBD (≤25 mg/week). Shea 2013 Cochrane (PMID 23728635, 6 RCTs, n=624) confirmed: 26% relative reduction in GI side effects, 77% reduction in abnormal transaminase elevation, 61% reduction in MTX discontinuation. Importantly, folic and folinic acid did NOT reduce MTX efficacy on tender/swollen joint counts or physician's global assessment. The 'folate antagonizes MTX' concern applies to oncology-dose chemotherapy (where folate replenishes the pool MTX is designed to deplete), not to the 7.5–25 mg/week regimen used for autoimmune disease. The calculator hard-refuses oncology MTX and redirects to oncologist supervision; for low-dose MTX the standard regimen is 1000 µg/day folic acid daily, with folinic acid (leucovorin) 2.5–5 mg/week as the upgrade if GI symptoms persist.

Question 9

What's the difference between folic acid and folinic acid? Why does the MTX-adjunct goal mention both?

Accepted Answer

Folic acid is the synthetic form taken by mouth — it requires conversion by dihydrofolate reductase (DHFR) to active reduced folate. MTX inhibits DHFR; that's how the drug works. Folinic acid (calcium leucovorin) is already a reduced folate — it bypasses DHFR entirely and provides direct rescue of the depleted folate pool. For most RA patients on MTX, folic acid 1000 µg/day is sufficient and cheap. If GI symptoms persist on folic acid, the calculator recommends switching to folinic acid 2.5–5 mg/week 24 hours after the MTX dose — a more potent rescue that bypasses the inhibited enzyme. Folinic acid requires a prescription in most jurisdictions and is more expensive (~$25–50/month vs $3–10 for folic acid).

Folate Multi-Goal Calculator